Financial Performance - The unaudited revenue for the Group for the three months ended March 31, 2023, was approximately S$309,000, a decrease of approximately S$450,000 or 59.29% compared to S$759,000 for the same period in 2022[10]. - The unaudited loss for the Group was approximately S$1,827,000 for the three months ended March 31, 2023, representing a decrease in losses of approximately S$250,000 or 12.04% compared to a loss of S$2,077,000 for the same period in 2022[10]. - Loss per share for the Company was approximately 0.15 Singapore cents for the three months ended March 31, 2023, compared to 0.22 Singapore cents for the same period in 2022[10]. - Total comprehensive loss for the period was S$1,535,000, compared to S$2,055,000 for the same period in 2022[11]. - The Group's loss before tax was S$1,827,000 for the three months ended March 31, 2023[11]. - The company reported a loss before taxation of S$1,826,000 for the three months ended March 31, 2023, compared to a loss of S$2,077,000 in the same period last year, showing an improvement[34]. - The total comprehensive loss for the same period in 2022 was S$2,507,000, indicating a year-over-year improvement in performance[13]. Revenue Sources - Revenue analysis indicates that the Group's revenue is derived from the provision of medical, dermatological, and aesthetic services and products[15]. - Revenue from dental services was S$264,000, while trading sales contributed S$45,000, indicating a significant shift in revenue sources[34]. - Revenue from Hong Kong was S$45,000, down from S$759,000 in the previous year, while revenue from China was S$264,000, reflecting a new market focus[36]. - Revenue from Dental Services amounted to S$264,000, accounting for approximately 85% of total revenue for the three months ended March 31, 2023[63]. - Total revenue for the three months ended March 31, 2023, was S$309,000, a decrease of 59.3% compared to S$759,000 for the same period in 2022[31]. Operating Income and Expenses - Other operating income increased to S$572,000 for the three months ended March 31, 2023, compared to S$73,000 for the same period in 2022[11]. - Employee benefits expense was S$797,000 for the three months ended March 31, 2023, compared to S$765,000 for the same period in 2022[11]. - Depreciation of plant and equipment increased to S$68,000 for the three months ended March 31, 2023, from S$33,000 for the same period in 2022[11]. - Other operating expenses rose by approximately S$296,000 or 30.42%, from approximately S$973,000 for the three months ended March 31, 2022, to approximately S$1,269,000 for the same period in 2023[88]. - Consumables and medical supplies used amounted to approximately S$163,000 for the three months ended March 31, 2023, down from S$638,000 in the same period in 2022[68]. Corporate Governance - The Company complied with all applicable code provisions of the Corporate Governance Code during the three months ended March 31, 2023[110]. - The Board is committed to high standards of corporate governance to manage business risks and enhance transparency[109]. - The Company is continuously reviewing and improving its corporate governance practices[109]. - All directors confirmed compliance with the required standard of dealings and the code of conduct regarding securities transactions throughout the three months ended March 31, 2023[122]. - The company has established an Audit Committee in compliance with GEM Listing Rules, consisting of three independent non-executive directors[136]. Share Options and Equity - The company recognized S$344,000 from the exercise of share options during the period[13]. - The total number of share options granted as of March 31, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[118]. - The Company has a Share Option Scheme that allows for the exercise of options from September 29, 2022, to September 28, 2032, at an exercise price of HK$0.109 per share[115]. - As of March 31, 2023, the total equity was reported at S$7,396,000, a decrease from S$6,288,000 at January 1, 2023[13]. - The weighted average number of ordinary shares in issue increased to 1,231,793,000 for the three months ended March 31, 2023, compared to 930,000,000 in the previous year[48]. Future Strategies - The core business operations will shift to dental implant services, with a two-year business development plan established in 2022[54]. - The Company sees significant market potential for dental implant services in mainland China due to its large population and aging demographic[55]. - Future strategies may include further market expansion and potential new product offerings in the healthcare sector[34]. - The company is focusing on expanding its dental services, which have shown growth potential in the current market[34]. Taxation and Compliance - The company has not reported any current tax expenses for the period, maintaining a tax rate of 17% for Singapore corporate income tax[43]. - Income tax expense remained nil for the three months ended March 31, 2022, and 2023, indicating no taxable income during these periods[90].
德斯控股(08437) - 2023 Q4 - 季度业绩